Brief: Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results Of Phase 2 Tellomak Study With Updated Olsen Criteria
16/06/2023 06:02
June 16 (Reuters) - Innate Pharma SA IPH.PA :
* INNATE PHARMA HIGHLIGHTS INCREASED LACUTAMAB CLINICAL
ACTIVITY
FROM INTERIM RESULTS OF PHASE 2 TELLOMAK STUDY WITH UPDATED
OLSEN CRITERIA
* UPDATED GLOBAL ORR OF 42.9% IN HEAVILY PRETREATED
KIR3DL2-EXPRESSING PATIENTS WITH MYCOSIS FUNGOIDES
Source text for Eikon: ID:nBw9DkvJ4a
Further company coverage: IPH.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Innate Pharma SA
See all newsFrance's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member
French and Benelux stocks-Factors to watch